Results 41 to 50 of about 25,087 (209)

Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor

Clinical and Translational Science
Venetoclax, a highly potent BCL‐2 inhibitor, is indicated for treatment of some hematologic malignancies as monotherapy, and/or in combination with other agents.
Ahmed Hamed Salem, Rajeev M. Menon
doaj   +1 more source

Dual targeting of MDM2 and BCL2 as a therapeutic strategy in neuroblastoma [PDF]

, 2017
Wild-type p53 tumor suppressor activity in neuroblastoma tumors is hampered by increased MDM2 activity, making selective MDM2 antagonists an attractive therapeutic strategy for this childhood malignancy.
Barbieri, Eveline, Moreno-Smith, Myrthala, Shohet, Jason, Speleman, Franki, Van Goethem, Alan, Van Maerken, Tom, Vandesompele, Jo, Vasudevan, Sanjeev A, Yigit, Nurten   +8 more
core   +3 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

PICALM::MLLT10 translocated leukemia

FEBS Letters, EarlyView.
This comprehensive review of PICALM::MLLT10 translocated acute leukemia provides an in‐depth review of the structure and function of CALM, AF10, and the fusion oncoprotein (1). The multifaceted molecular mechanisms of oncogenesis, including nucleocytoplasmic shuttling (2), epigenetic modifications (3), and disruption of endocytosis (4), are then ...
John M. Cullen, Antonia C. Nakatsugawa, Natalie Barton, Henry Haines, Gary S. Stein, Janet L. Stein, Daniel S. Wechsler, Jessica L. Heath   +7 more
wiley   +1 more source

Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines

Cardio-Oncology
Venetoclax is a promising drug for patients with acute myeloid leukemia (AML) ineligible for anthracycline-based treatments. In rats, venetoclax is reported to cause myocardial injury.
Takeshi Onoue, Andrew H. Matthews, Azin Vakilpour, Yu Kang, Bénédicte Lefebvre, Amanda M. Smith, Shannon R. McCurdy, Michael G. Fradley, Joseph Carver, Jesse Chittams, Marielle Scherrer-Crosbie   +10 more
doaj   +1 more source

Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia

Frontiers in Oncology, 2022
B-cell receptor (BCR) signaling pathway and Bcl-2 family prosurvival proteins, specifically Bcl-2 and Mcl-1, are functional in the pathobiology of chronic lymphocytic leukemia (CLL).
Xue Yi, Nitin Jain, LaKesla R. Iles, Mary L. Ayres, William G. Wierda, Varsha Gandhi, Varsha Gandhi   +6 more
doaj   +1 more source

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia [PDF]

, 2017
Drug sensitivity and resistance testing on diagnostic leukemia samples should provide important functional information to guide actionable target and biomarker discovery.
Balasubramanian, Gnana P., Bandapalli, Obul R., Bornhauser, Beat C., Bourquin, Jean-Pierre, Brown, Timothy J., Cario, Gunnar, Chang, Bill H., Collins, Robert H., Delorenzi, Mauro, Diaz-Flores, Ernesto, Dobay, Maria Pamela, Dunn, Samuel H., Eckert, Cornelia, Eugster, Sabrina, Frismantas, Viktoras, Higi, Salome, Horvath, Peter, Irving, Julie A., Jenni, Silvia, Kulozik, Andreas E., Kunz, Joachim, Loh, Mignon L., Marovca, Blerim, Meisel, Roland, Muckenthaler, Martina U., Pail, Orrin, Radimerski, Thomas, Richter-Pechanska, Paulina, Rinaldi, Anna, Saha, Vaskar, Schrappe, Martin, Stanulla, Martin, Tchinda, Joelle, Tyner, Jeffrey W., Uhrig, Sebastian, Voegeli, Pamela, Von Stackelberg, Arend   +36 more
core   +1 more source

Cell wall target fragment discovery using a low‐cost, minimal fragment library

FEBS Letters, EarlyView.
LoCoFrag100 is a fragment library made up of 100 different compounds. Similarity between the fragments is minimized and 10 different fragments are mixed into a single cocktail, which is soaked to protein crystals. These crystals are analysed by X‐ray crystallography, revealing the binding modes of the bound fragment ligands.
Kaizhou Yan, Mathew Stanley, Olawale Raimi, Andrew T. Ferenbach, Helge C Dorfmueller, Daan M. F. van Aalten   +5 more
wiley   +1 more source

Paired comparisons of venetoclax concentration in cerebrospinal fluid, bone marrow, and plasma in acute leukemia patients

Clinical and Translational Science
Venetoclax, a small molecule inhibitor of BCL‐2, has demonstrated efficacy in treating acute leukemias and has been recommended as one of the first‐line anti‐leukemia therapies.
Yuan Jian, Feifei Han, Ying Zhu, Chuanying Geng, Yanru Zhang, Yin Wu, Yun Leng, Wenming Chen, Zhuoling An, Hong‐Hu Zhu   +9 more
doaj   +1 more source

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia

Haematologica, 2023
Venetoclax+azacitidine is the standard of care for newly-diagnosed patients with acute myeloid leukemia (AML) for whom intensive chemotherapy is inappropriate. Efforts to optimize this regimen are necessary.
Jonathan A. Gutman, Amanda Winters, Andrew Kent, Maria Amaya, Christine McMahon, Clayton Smith, Craig T. Jordan, Brett Stevens, Mohammad Minhajuddin, Shanshan Pei, Jeffrey Schowinsky, Jennifer Tobin, Kelly O’Brien, Angela Falco, Elizabeth Taylor, Constance Brecl, Katie Zhou, Phuong Ho, Connor Sohalski, Jessica Dell-Martin, Olivia Ondracek, Diana Abbott, Daniel A. Pollyea   +22 more
doaj   +1 more source